Trial Profile
A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferitazole (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Sponsors Shire
- 14 Aug 2015 Changed primary endpoint from pharmacokinetic parameters to change from baseline in Liver Iron Concentration (LIC) as reported by ClinicalTrial.gov record.
- 28 Nov 2014 New trial record